Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
vilastobart · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A - vilastobart (XTX101) Monotherapy Dose Escalation | EXPERIMENTAL | Part 1A Dose Escalation of vilastobart (XTX101) administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D). |
| Part 1B - Pharmacodynamic (PD) Dose Expansion | EXPERIMENTAL | Part 1B vilastobart (XTX101) at the RP2D will be administered to further examine vilastobart (XTX101) as monotherapy in patients with select advanced solid tumors. |
| Part 1C - vilastobart (XTX101) Dose Escalation and Dose Expansion in Combination with Atezolizumab | EXPERIMENTAL | Part 1C will receive a labeled dose of atezolizumab in combination with vilastobart (XTX101). |
| Phase 2 - vilastobart (XTX101) Dose Expansion in Combination with Atezolizumab | EXPERIMENTAL | Phase 2 will receive a labeled dose of atezolizumab in combination with vilastobart (XTX101) at the RP2D(s) in patients with MSS CRC. |
| Name | Type | Description |
|---|---|---|
| vilastobart (XTX101) | DRUG | vilastobart (XTX101) monotherapy |
| Atezolizumab | DRUG | 1200 mg administered every 3 weeks in combination with vilastobart (XTX101) |
Inclusion Criteria: Disease Criteria - * Part 1A and 1C: Any histologically or cytologically confirmed solid tumor malignancy that is locally advanced or metastatic and has failed standard therapy, or standard therapy is not curative or available; * Part 1B: * Any histologically or cytologicall...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Vilastobart is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors.
Vilastobart is being developed by Xilio Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol XLO. The company is conducting clinical trials to evaluate the safety and efficacy of vilastobart in patients with advanced solid tumors.
Vilastobart is currently in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The Phase 1 trial has been completed, and the drug is being studied for the treatment of advanced solid tumors.
Vilastobart has been studied in a Phase 1 clinical trial with the identifier NCT04896697. This trial evaluated vilastobart as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors. The trial was conducted in the United States and enrolled 125 participants.
Yes, vilastobart is also known as XTX101. The clinical trial NCT04896697, which evaluated vilastobart, is titled 'Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors.' Both names refer to the same investigational drug.